PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDulanermin
Dulanermin
Dulanermin is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
44 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombosisD01392711
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3224
NeoplasmsD009369C80213
Non-small-cell lung carcinomaD002289112
Iga glomerulonephritisD005922EFO_0004194112
Hemolytic anemia autoimmuneD000744EFO_1001264D59.10112
Neuromyelitis opticaD009471EFO_0004256G36.011
Lung neoplasmsD008175C34.9011
Lung diseasesD008171EFO_0003818J98.411
Bronchogenic carcinomaD00228311
Thoracic neoplasmsD01389911
Show 1 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228C85.9515
Systemic sclerodermaD012595EFO_0000717M34224
Diffuse sclerodermaD045743EFO_0000404224
Systemic lupus erythematosusD008180EFO_0002690M321113
SclerosisD012598112
LeukemiaD007938C95212
B-cell chronic lymphocytic leukemiaD015451C91.1212
Psychologic desensitizationD00388711
B-cell leukemiaD015448111
MelanomaD00854511
Show 9 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell lymphomaD01639344
LymphomaD008223C85.933
Mantle-cell lymphomaD020522C83.133
Colorectal neoplasmsD01517922
B-cell lymphoma marginal zoneD018442C88.422
Follicular lymphomaD008224C8222
Large b-cell lymphoma diffuseD016403C83.322
Colonic neoplasmsD003110C1811
LymphopeniaD008231D72.81011
Idiopathic cd4-positive t-lymphocytopeniaD018344EFO_000732211
Show 12 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Localized sclerodermaD012594EFO_1001361L94.022
HyperprolactinemiaD006966E22.111
HyperphagiaD006963R63.211
Obstructive jaundiceD041781EFO_100106811
JaundiceD007565R1711
PregnancyD011247EFO_0002950Z33.111
Kidney transplantationD01603011
Graft rejectionD00608411
FeverD005334R50.911
Virus diseasesD014777B3411
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDulanermin
INNdulanermin
Description
Dulanermin is a protein pharmaceutical. It is currently being investigated in clinical studies.
Classification
Protein
Drug classgrowth factors: tumor necrosis factors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL2107846
ChEBI ID
PubChem CID
DrugBank
UNII IDL65E7T81M5 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,867 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use